Table 3 Simple summary of different studies on improving all-cause mortality after bisphosphonates treatment in patients with hip fractures
From: All-cause mortality risk in aged femoral intertrochanteric fracture patients
References | Anti-OP drug | Use time | Frequency | Fracture type | Race or region | Research type | Treated cases N | Age | Mean follow-up time (M) | HR (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|---|---|---|
Lyles et al. [45] | ZOL | ≤ 90 days after surgical | Yearly | Hip fracture | No Asia | Randomized, double-blind, placebo-controlled trial | 1065 | ≥ 50 | 22.8 | 0.72 (0.56, 0.93) | 0.01 |
Eriksen et al. [46] | ZOL | ≤ 2 week after surgical | Yearly | Hip fracture | No Asia | Randomized, double-blind, placebo-controlled trial | 56 | ≥ 50 | 22.8 | – | > 0.05 |
Bergman et al. [47] | ZOL | – | – | Hip fracture | Sweden | Retrospective cohort study | 161 | ≥ 50 | 33.6 | 1.51 (1.00, 2.28) | 0.048 |
Wang et al. [48] | ZOL | ≤ 2 weeks after admission | – | Hip fracture | China | Retrospective study | 80 | ≥ 50 | 28.5 | 0.36 (0.19, 0.65) | < 0.01 |
Brozek et al. [49] | All BP and Denosumab | ≤ 1 year | – | Hip fracture | Austria | Retrospective nationwide cohort study | 2166 | ≥ 50 | 36 | 0.48 (0.42, 0.55) | < 0.0001 |
Bergman et al. [47] | Alendronate | – | – | Hip fracture | Sweden | Retrospective cohort study | 4689 | ≥ 50 | 33.6 | 0.82 (0.76, 0.89) | < 0.001 |
Bondo et al. [50] | Oral BP | 5 month after fracture | > 2 packs | Hip fracture | Danish | Nationwide register-based open cohort study | 1096 | ≥ 55 | 45.6 | 0.73 (0.61, 0.88) | 0.001 |
Axelsson et al. [51] | Alendronate | – | ≥ 3 months | Hip fracture | Sweden | Prospective observational register-based study | 1961 | ≥ 80 | 19.2 | 0.88 (0.82, 0.95) | < 0.01 |
Beaupre et al. [52] | Oral BP | 1 and 2 years | 64% yearly | Hip fracture | Canada | Randomized controlled trial | 101 | > 50 | 36 | 0.92 (0.88, 0.97) | 0.001 |
Van Geel et al. [53] | Oral BP | 2 weeks later | Continued 5 years | Clinical fracture (21.7% for hip fracture) | Scotland | Prospective cohort study | 2534 | ≥ 50 | 44.9 | 0.79 (0.64, 0.97) | 0.021 |
This study | ZOL | ≤ 3 days after surgical | Once | Intertrochanteric fracture | China | Prospective cohort study | 139 | ≥ 65 | 23.5 | 0.33 (0.16–0.71) | 0.005 |